Nuvalent [NUVL] vs Corcept Therapeutics [CORT] Detailed Stock Comparison
Nuvalent
NASDAQ
Loading...
Corcept Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Nuvalent wins in 4 metrics, Corcept Therapeutics wins in 11 metrics, with 0 ties. Corcept Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nuvalent | Corcept Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -21.43 | 78.71 | Nuvalent |
| Price-to-Book Ratio | 6.45 | 14.60 | Nuvalent |
| Debt-to-Equity Ratio | 0.00 | 1.04 | Nuvalent |
| PEG Ratio | -0.37 | -26.76 | Corcept Therapeutics |
| EV/EBITDA | -18.07 | 87.24 | Nuvalent |
| Profit Margin (TTM) | 0.00% | 18.67% | Corcept Therapeutics |
| Operating Margin (TTM) | 0.00% | 13.72% | Corcept Therapeutics |
| EBITDA Margin (TTM) | N/A | 13.72% | N/A |
| Return on Equity | -43.55% | 21.70% | Corcept Therapeutics |
| Return on Assets (TTM) | -26.37% | 8.36% | Corcept Therapeutics |
| Free Cash Flow (TTM) | $-185.06M | $195.90M | Corcept Therapeutics |
| 1-Year Return | -19.06% | 97.78% | Corcept Therapeutics |
| Price-to-Sales Ratio (TTM) | N/A | 12.97 | N/A |
| Enterprise Value | $5.07B | $8.95B | Corcept Therapeutics |
| EV/Revenue Ratio | N/A | 12.50 | N/A |
| Gross Profit Margin (TTM) | N/A | 98.23% | N/A |
| Revenue per Share (TTM) | $0 | $7 | Corcept Therapeutics |
| Earnings per Share (Diluted) | $-4.92 | $1.12 | Corcept Therapeutics |
| Beta (Stock Volatility) | 1.30 | 0.46 | Corcept Therapeutics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Nuvalent vs Corcept Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nuvalent | -0.56% | -1.17% | 5.04% | 7.60% | 29.64% | 4.83% |
| Corcept Therapeutics | 0.52% | 7.09% | 26.14% | 33.01% | 20.36% | 79.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nuvalent | -19.06% | 304.49% | 359.45% | 359.45% | 359.45% | 359.45% |
| Corcept Therapeutics | 97.78% | 230.09% | 399.17% | 2,197.95% | 2,308.85% | 1,704.22% |
News Based Sentiment: Nuvalent vs Corcept Therapeutics
Nuvalent
News based Sentiment: MIXED
October was a pivotal month for Nuvalent, marked by a significant regulatory milestone with the NDA submission for zidesamtinib. However, the substantial insider selling activity introduces a note of caution, creating a mixed investment narrative despite positive analyst coverage and upcoming data catalysts.
Corcept Therapeutics
News based Sentiment: MIXED
October presented a mixed bag for Corcept, with continued strength in Korlym sales overshadowed by lowered revenue guidance and concerning insider selling. The upcoming FDA decisions on relacorilant remain the key driver of potential upside, but near-term challenges and market uncertainty create a complex investment picture.
Performance & Financial Health Analysis: Nuvalent vs Corcept Therapeutics
| Metric | NUVL | CORT |
|---|---|---|
| Market Information | ||
| Market Cap | $6.23B | $9.29B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 411,770 | 733,300 |
| 90 Day Avg. Volume | 420,070 | 831,183 |
| Last Close | $83.38 | $90.32 |
| 52 Week Range | $55.53 - $106.32 | $42.01 - $117.33 |
| % from 52W High | -21.58% | -23.02% |
| All-Time High | $113.51 (Sep 16, 2024) | $117.33 (Mar 31, 2025) |
| % from All-Time High | -26.54% | -23.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.19% |
| Quarterly Earnings Growth | N/A | -0.01% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.19% |
| Operating Margin (TTM) | 0.00% | 0.14% |
| Return on Equity (TTM) | -0.44% | 0.22% |
| Debt to Equity (MRQ) | 0.00 | 1.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.05 | $6.04 |
| Cash per Share (MRQ) | $13.95 | $3.25 |
| Operating Cash Flow (TTM) | $-239,236,000 | $182.19M |
| Levered Free Cash Flow (TTM) | $-121,000,128 | $166.88M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Nuvalent vs Corcept Therapeutics
| Metric | NUVL | CORT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -21.43 | 78.71 |
| Forward P/E | -19.86 | 50.37 |
| PEG Ratio | -0.37 | -26.76 |
| Price to Sales (TTM) | N/A | 12.97 |
| Price to Book (MRQ) | 6.45 | 14.60 |
| Market Capitalization | ||
| Market Capitalization | $6.23B | $9.29B |
| Enterprise Value | $5.07B | $8.95B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 12.50 |
| Enterprise to EBITDA | -18.07 | 87.24 |
| Risk & Other Metrics | ||
| Beta | 1.30 | 0.46 |
| Book Value per Share (MRQ) | $13.05 | $6.04 |
Financial Statements Comparison: Nuvalent vs Corcept Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NUVL | CORT |
|---|---|---|
| Revenue/Sales | $0 | $157.21M |
| Cost of Goods Sold | N/A | $2.40M |
| Gross Profit | N/A | $154.81M |
| Research & Development | $80.91M | $60.74M |
| Operating Income (EBIT) | $-104.57M | $3.42M |
| EBITDA | $-104.57M | $3.88M |
| Pre-Tax Income | $-99.51M | $9.62M |
| Income Tax | $145,000 | $-10.93M |
| Net Income (Profit) | $-99.65M | $20.55M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NUVL | CORT |
|---|---|---|
| Cash & Equivalents | $120.84M | $89.82M |
| Total Current Assets | $1.09B | $438.50M |
| Total Current Liabilities | $75.03M | $143.07M |
| Long-Term Debt | N/A | $5.85M |
| Total Shareholders Equity | $1.01B | $683.29M |
| Retained Earnings | $-631.63M | $564.28M |
| Property, Plant & Equipment | N/A | $7.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NUVL | CORT |
|---|---|---|
| Operating Cash Flow | $-50.98M | $34.72M |
| Capital Expenditures | N/A | $-104,000 |
| Free Cash Flow | $-54.82M | $5.02M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NUVL | CORT |
|---|---|---|
| Shares Short | 5.33M | 10.81M |
| Short Ratio | 12.95 | 16.33 |
| Short % of Float | 0.17% | 0.14% |
| Average Daily Volume (10 Day) | 411,770 | 733,300 |
| Average Daily Volume (90 Day) | 420,070 | 831,183 |
| Shares Outstanding | 71.34M | 105.11M |
| Float Shares | 41.56M | 86.95M |
| % Held by Insiders | 0.03% | 0.12% |
| % Held by Institutions | 1.09% | 0.76% |
Dividend Analysis & Yield Comparison: Nuvalent vs Corcept Therapeutics
| Metric | NUVL | CORT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |